AML-VAC-XS15-01: Multi-peptide vaccination adjuvanted with the TLR1/2 ligand XS15 in acute myeloid leukemia (AML) patients who have achieved complete remission with first line therapy
Phase 1
- Conditions
- acute myeolic leukemiaMedDRA version: 21.0Level: LLTClassification code: 10000886Term: Acute myeloid leukemia Class: 10029104Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]
- Registration Number
- CTIS2023-510316-39-00
- Lead Sponsor
- niversitaetsklinikum Tuebingen AöR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method